*The following content is generated by AI and is for reference only.
Gliclazide is a second-generation sulfonylurea antidiabetic agent widely utilized in the management of type 2 diabetes mellitus. With the Chemical Abstracts Service (CAS) registry number 2170-82-9, this compound possesses the molecular formula C15H21N3O3S and a molecular weight of approximately 323.41 g/mol. Structurally characterized by a bicyclic hexahydro-1H-benzo[d]azepine core linked to a sulfonamide group, Gliclazide functions primarily by stimulating insulin secretion from pancreatic beta cells. Unlike some other agents in its class, it exhibits a relatively high affinity for the SUR1 subunit of the ATP-sensitive potassium channels, facilitating glucose-dependent insulin release with a lower risk of hypoglycemia compared to first-generation derivatives.
Clinically, Gliclazide is indicated as an adjunct to diet and exercise for patients who are not adequately controlled by lifestyle modifications alone. It is particularly valued for its ability to improve glycemic control without significant weight gain, making it a preferred choice for many clinicians. The drug is available in various formulations, including immediate-release tablets and modified-release (MR) capsules, allowing for flexible dosing regimens tailored to individual patient needs. Its pharmacokinetic profile features rapid absorption and a half-life that supports once-daily or twice-daily administration depending on the specific formulation used. Furthermore, emerging research suggests potential benefits beyond glycemic control, including possible antioxidant properties that may help mitigate diabetic microvascular complications such as retinopathy and nephropathy. While generally well-tolerated, common side effects may include gastrointestinal disturbances, headaches, and rare instances of allergic reactions. As a cornerstone medication in global diabetes care, Gliclazide remains essential for maintaining long-term metabolic stability and preventing disease progression in millions of patients worldwide.